医薬品新興国市場2017-2021

【英語タイトル】Global Pharmerging Markets 2017-2021

Technavioが出版した調査資料(IRTNTR11577)・商品コード:IRTNTR11577
・発行会社(調査会社):Technavio
・発行日:2017年1月16日
・ページ数:116
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:ブラジル、ロシア、中国、インド、トルコ、メキシコ、韓国
・産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名利用)USD3,500 ⇒換算¥395,500見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,500 ⇒換算¥508,500見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥565,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日~2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
当調査レポートでは、医薬品新興国市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、医薬品新興国市場規模及び予測、地域別分析/市場規模、市場の成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。
【レポートの概要】

About Pharmerging
The immense growth potential in pharmerging market has driven large multinational pharmaceutical companies to focus on these regions by pursuing organic as well as in-organic routes. To make in-roads into the new geography, the large players usually take in-organic route through strategic expansion initiatives such as acquisitions and alliances. For instance, in December 2015, AstraZeneca entered into a deal with WuXi to acquire its biologics manufacturing facilities in China to expand locally.

Technavio’s analysts forecast the global pharmerging market to grow at a CAGR of 12.88% during the period 2017-2021.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global pharmerging market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of pharmaceutical drugs in pharmerging markets, which are further divided into Tier I, II and III.

The market is divided into the following segments based on geography:
• Tier 1
• Tier 2
• Tier 3

Technavio’s report, Global Pharmerging Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• AstraZeneca
• GlaxoSmithKline
• Pfizer
• Sanofi
• Novartis

[Other prominent vendors]
• Abbott Laboratories
• AbbVie
• Alexion Pharmaceuticals
• Allergan
• Amgen
• Aspen
• Astellas Pharma
• Baxter
• Bayer
• Biogen
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Celgene
• CSL Behring
• Daiichi Sankyo
• Dainippon Sumitomo Pharma
• Eisai
• Eli Lilly
• Endo Health Pharmaceuticals
• F. Hoffmann-La Roche
• Fresenius
• Gilead
• Grifols
• H. Lundbeck
• Hospira
• Johnson & Johnson
• Kyowa Hakko Kirin
• Mallinckrodt Pharmaceuticals
• Menarini
• Mitsubishi Tanabe Pharma
• Mylan
• Novo Nordisk
• Otsuka
• Shire
• STADA Arzneimittel
• Sun Pharmaceutical
• Takeda Pharma
• Teva Pharmaceutical Industries
• UCB
• Valeant Pharmaceuticals

[Market driver]
• Limitations in developed economies fuels demand in emerging economies
• For a full, detailed list, view our report

[Market challenge]
• Stringent price control and generic -centric usage lead to value erosion
• For a full, detailed list, view our report

[Market trend]
• Potential of new countries in emerging markets
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

About Thoracic Surgery

Thoracic surgery involves surgical treatment (open surgery or minimally invasive surgery) to address medical conditions involving the heart or lungs. It includes procedures such as redo heart surgery, aortic dissection for aortic surgery, minimally invasive mitral valve repair and replacement, and endovascular repair of thoracic aortic aneurysms. It is performed to treat end-stage heart failure, heart-lung transplants, and placement of ventricular-assist devices.

Technavio’s analysts forecast the global thoracic surgery market to grow at a CAGR of 10.16% during the period 2016-2020.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global thoracic surgery market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of medical devices required for thoracic surgeries.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Thoracic Surgery Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• Boston Scientific
• Medtronic
• Sorin
• St. Jude Medical
• Terumo

[Other prominent vendors]
• Abbott Vascular
• Abiomed
• AtriCure
• Biosensors International
• Biotronik
• BioVentrix
• C. R. Bard

[Market driver]
• Rise in incidence of cardiac disorders and increase in aging population
• For a full, detailed list, view our report

[Market challenge]
• Potential complications associated with cardiac surgery
• For a full, detailed list, view our report

[Market trend]
• Growing popularity of robot-assisted cardiac surgery
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【レポートの目次】

Table of Contents
PART 01: Executive summary

PART 02: Scope of the report
• Market overview

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights
• Highlights

PART 05: Global pharmaceutical market
• Market size and forecast

PART 06: Road to pharmerging markets

PART 07: Pharmerging markets

PART 08: Market landscape
• Medicine spending in emerging economies
• Five forces analysis

PART 09: Market segmentation by geography

PART 10: Market overview of tier I countries
• China

PART 11: Market overview of tier II countries
• Brazil
• Russia
• India

PART 12: Market overview of tier III countries
• Market size and forecast

PART 13: Market drivers
• Limitations in developed economies fuels demand in emerging economies
• Increasing focus toward biosimilar in potential areas
• Expansion initiatives of vendors

PART 14: Impact of drivers

PART 15: Market challenges
• IP protection issues
• Socio-political issues in cross geography transactions
• Stringent price control and generic-centric usage lead to value erosion

PART 16: Impact of drivers and challenges

PART 17: Market trends
• Potential of new countries in emerging markets
• Positive outlook toward adoption of targeted therapies
• Evolving stakeholder landscape to change market dynamics

PART 18: Vendor landscape
• Competitive scenario

PART 19: Key vendor analysis
• AstraZeneca
• GlaxoSmithKline
• Pfizer
• Sanofi
• Novartis
• Other prominent vendors

PART 20: Appendix
• List of Abbreviations

PART 21: Explore Technavio

[List of Exhibits]

Exhibit 01: Global country rankings in pharmaceutical market based on healthcare spending
Exhibit 02: Global pharmaceutical market 2016-2021 ($ trillions)
Exhibit 03: Drivers, challenges and trends of global pharmaceutical market
Exhibit 04: Growth comparision between developed markets and pharmerging markets
Exhibit 05: Share of pharmerging markets in global pharmaceutical market, 2016
Exhibit 06: Snapshot of key pharmerging markets
Exhibit 07: Regulatory landscape in key pharmerging markets
Exhibit 08: Pharmerging markets 2016-2021 ($ billions)
Exhibit 09: Comparison of medicine spending in developed economies and pharmerging markets
Exhibit 10: Medicine spending and growth rates in pharmerging markets
Exhibit 11: Standard units in 2021 by product type in pharmerging countries
Exhibit 12: Expected medicine spending by geography
Exhibit 13: Volume growth and population with more than $5,000/year income by country 2016
Exhibit 14: Percentage share of pharmerging markets in global pharmaceutical market 2016-2021
Exhibit 15: Percentage share of tier I, II and III countries in total pharmerging markets 2016-2021
Exhibit 16: Pharmerging markets share by country, 2016
Exhibit 17: Five forces analysis
Exhibit 18: Pharmerging markets segment by geography
Exhibit 19: Geographic representation of tier I country
Exhibit 20: China GDP 2011-2015 ($ trillions) and healthcare expenditure 2010-2014 (% of GDP)
Exhibit 21: On-going healthcare reforms in China
Exhibit 22: Segmentation of Chinese pharmaceutical market
Exhibit 23: Segment analysis in Chinese pharmaceutical market
Exhibit 24: Regulatory bodies
Exhibit 25: Major therapy areas based on sales of drugs, 2016
Exhibit 26: Major acquisitions in Chinese pharmaceutical market 2014-2016
Exhibit 27: Drivers and challenges in Chinese pharmaceutical market
Exhibit 28: Pharmaceutical market in China 2016-2021 ($ billions)
Exhibit 29: China pharmaceutical market: SWOT analysis
Exhibit 30: Geographic representation of tier II countries
Exhibit 31: Pharmaceutical market in tier II countries 2016-2021 ($ billions)
Exhibit 32: Brazil GDP 2011-2015 ($ trillions) and healthcare expenditure 2010-2014 (% of GDP)
Exhibit 33: Regulatory bodies
Exhibit 34: Segmentation of pharmaceutical market in Brazil 2016
Exhibit 35: Major acquisitions in Brazil pharmaceutical market
Exhibit 36: Drivers and challenges in Brazilian pharmaceutical market
Exhibit 37: Pharmaceutical market in Brazil 2016-2021 ($ billions)
Exhibit 38: Brazil pharmaceutical market: SWOT analysis
Exhibit 39: Russia GDP 2011-2015 ($ trillions) and healthcare expenditure 2010-2014 (% of GDP)
Exhibit 40: Major acquisitions in Russian pharmaceutical market
Exhibit 41: Drivers and challenges in Russian pharmaceutical market
Exhibit 42: Pharmaceutical market in Russia 2016-2021 ($ billions)
Exhibit 43: Russia pharmaceutical market: SWOT analysis
Exhibit 44: India GDP 2011-2015 ($ trillions) and healthcare expenditure 2010-2014 (% of GDP)
Exhibit 45: Regulatory landscape
Exhibit 46: Major acquisitions in pharmaceutical sector in India
Exhibit 47: Drivers and challenges in Indian pharmaceutical market
Exhibit 48: Pharmaceutical market in India 2016-2021 ($ billions)
Exhibit 49: India pharmaceutical market: SWOT analysis
Exhibit 50: Geographic representation of tier III countries
Exhibit 51: Pharmaceutical market in tier III countries 2016-2021 ($ billions)
Exhibit 52: Revenues from pharmaceuticals for few of the tier III countries 2016 ($ billions)
Exhibit 53: Snapshot of key countries in tier III countries
Exhibit 54: Tier III countries pharmaceutical market: SWOT analysis
Exhibit 55: Factors that are driving the growth in emerging economies
Exhibit 56: Biosimilar development in emerging economies
Exhibit 57: Few acquisitions and their impact
Exhibit 58: Impact of drivers
Exhibit 59: Impact of drivers and challenges
Exhibit 60: Positioning of key vendors in pharmerging markets 2015
Exhibit 61: Competitive analysis snapshot
Exhibit 62: Top selling products in emerging markets 2015
Exhibit 63: Key takeaways
Exhibit 64: Key highlights in emerging markets
Exhibit 65: AstraZeneca strength assessment
Exhibit 66: Geographic segmentation by revenue 2015
Exhibit 67: Key takeaways
Exhibit 68: Key highlights in emerging markets
Exhibit 69: GSK strength assessment
Exhibit 70: Geographic segmentation by revenue 2015
Exhibit 71: Key takeaways
Exhibit 72: Pfizer: YoY and growth rate in emerging markets
Exhibit 73: Segmentation by revenue in emerging markets ($ millions)
Exhibit 74: Key highlights in emerging markets
Exhibit 75: Pfizer strength assessment
Exhibit 76: Pfizer: Geographical segmentation by revenue 2015
Exhibit 77: Top selling products0
Exhibit 78: Key emerging products0
Exhibit 79: Geographical segmentation by revenue1
Exhibit 80: Key takeaways2
Exhibit 81: Key highlights in emerging markets2
Exhibit 82: Sanofi strength assessment3
Exhibit 83: Key takeaways4
Exhibit 84: Key highlights in emerging markets5
Exhibit 85: Novartis strength assessment6
Exhibit 86: Novartis: Geographical segmentation by revenue 20156



【掲載企業】

AstraZeneca, GlaxoSmithKline, Pfizer, Sanofi, Novartis, Abbott Laboratories, AbbVie, Alexion Pharmaceuticals, Allergan, Amgen, Aspen, Astellas Pharma, Baxter, Bayer, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, CSL Behring, Daiichi Sankyo, Dainippon Sumitomo Pharma, Eisai, Eli Lilly, Endo Health Pharmaceuticals, F. Hoffmann-La Roche, Fresenius, Gilead, Grifols, H. Lundbeck, Hospira, Johnson & Johnson, Kyowa Hakko Kirin, Mallinckrodt Pharmaceuticals, Menarini, Mitsubishi Tanabe Pharma, Mylan, Novo Nordisk, Otsuka, Shire, STADA Arzneimittel, Sun Pharmaceutical, Takeda Pharma, Teva Pharmaceutical Industries, UCB, Valeant Pharmaceuticals.

【レポートのキーワード】

医薬品新興国市場

【調査方法】

Research methodology is based on extensive primary and secondary research. Primary research includes in-depth interviews with industry experts, vendors, resellers and customers. Secondary research includes Technavio Platform, industry publications, company reports, news articles, analyst reports, trade associations and the data published by Government agencies.

★調査レポート[医薬品新興国市場2017-2021] (コード:IRTNTR11577)販売に関する免責事項を必ずご確認ください。
★調査レポート[医薬品新興国市場2017-2021]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆